Beijing Immunocharm

Beijing Immunocharm is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of next-generation oncolytic virus therapies and mRNA-based cancer vaccines. The company utilizes its proprietary technology platforms to engineer viruses that selectively target and destroy cancer cells while simultaneously stimulating a systemic anti-tumor immune response. Their lead candidate, IM-01, is an oncolytic herpes simplex virus (oHSV) designed to express therapeutic payloads such as PD-L1 antibodies directly within the tumor microenvironment. Immunocharm's pipeline focuses on treating advanced solid tumors that are resistant to conventional immunotherapies. The company is backed by leading venture capital firms and aims to bridge the gap between viral therapy and personalized cancer vaccines.